Earnings call transcript: Shine Justice posts stronger underlying H2 2026 results

Shine Justice shares jumped 6.78% to $0.63 after reporting FY2026 adjusted revenue up 7.8% to AUD 220.4m and adjusted EBITDA up 13.9% to AUD 44.7m, with adjusted NPAT up 62.9% to AUD 15.8m (adjusted EPS +87% to 11.19c). Headline statutory results were muted by a AUD 13m legacy class-action one-off charge (AUD 11.2m revenue constraint write-down and AUD 1.8m disbursement impairments). Management guided further FY2027 growth (CFO “comfortable” with ~8% PI growth), while stating emerging technology benefits are not expected to show in financials until FY2028, supporting a positive but execution-dependent outlook.

Analysis

The real signal here is not revenue growth; it is that the business is showing operating leverage in a model where cash and earnings usually lag by quarters. When fee-earner productivity rises while WIP stays elevated, the next 2-4 quarters can look better than the reported statutory trend because recognized revenue catches up without a proportional step-up in fixed cost. That supports a higher multiple for SHJ over the next 6-18 months, but only if cash conversion improves and the company proves it can turn the backlog into realizable fees rather than just accumulated accounting assets.

The competitive read-through is more interesting than the headline print: a scaled plaintiff-law platform with national footprint, external funding access, and a U.S.-to-APAC sourcing model can pressure smaller boutique firms that still rely on balance-sheet-intensive case financing. The second-order effect is that funding partners may increasingly prefer larger intermediaries with better portfolio governance, which could widen the moat for SHJ and force weaker competitors into lower-return or more dilutive funding terms. The small positive read-through to CRM/MSFT exists, but it is deferred and low materiality; this is more a proof-of-concept vendor implementation than a near-term software monetization story.

Near term, the stock may already be discounting the "adjusted beat" and could fade if investors focus on the still-mediocre cash conversion and the fact that management pushed the technology payoff into FY28. The main falsifier is a miss on FY27 file intake / filing velocity or any deterioration in operating cash flow relative to EBITDA; that would indicate the growth pipeline is more timing than substance. Over 1-3 months, the catalyst set is earnings follow-through and funding conversion; over 6-18 months, the thesis depends on whether higher productivity and external funding translate into a structurally higher free cash flow margin.

Key Decisions for Investors

• Long SHJ on any pullback toward the post-result gap fill, with a 6-12 month horizon; thesis is that WIP conversion and funded class actions expand free cash flow before the market fully credits FY27/FY28 operating leverage.
• Use a tighter stop if operating cash conversion remains stuck near the low-40% of EBITDA range in the next update; that would indicate earnings quality is still too timing-dependent for a rerating.
• If liquidity allows, buy SHJ versus a basket of smaller plaintiff-law / litigation-funding names that lack balance-sheet capacity; the relative trade favors the platform with external funding access and broader pipeline optionality.
• Avoid chasing CRM/MSFT on this read-through; at most treat them as incidental vendor beneficiaries. Reassess only if SHJ starts quantifying measurable FY27 productivity savings or enterprise software spend expands materially.
• Set an alert on FY27 class-action filings and new-file acquisition pace; if those accelerate and cash flow inflects, add on confirmation. If they stall, fade the move and expect the multiple to compress back toward a value trap profile.